Source - RNS
RNS Number : 0731H
Hikma Pharmaceuticals Plc
02 June 2017






Hikma Pharmaceuticals PLC

Total Voting Rights and Capital


LONDON, 2 June 2017, Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75)
(LSE: HIK) (NasdaqDubai: HIK) notifies the market that its capital consists of 240,545,322

ordinary shares with voting rights. There are nil shares held in treasury.


The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FCA's Disclosure and Transparency Rules.


- ENDS -




Hikma Pharmaceuticals PLC



Peter Speirs

Company Secretary


+44 20 7399 2760




About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million.


This information is provided by RNS
The company news service from the London Stock Exchange